Vertex Pharmaceuticals Incorporated
Price Action
Technical Summary
CONSOLIDATINGVertex Pharmaceuticals Incorporated is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 75), indicating performance broadly in line with the market. Earnings growth of 61% provides fundamental context to the price action. However, with RSI at 81, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $470.47 | +12.57% | ABOVE |
| 50 SMA | $448.76 | +18.01% | ABOVE |
| 100 SMA | $454.15 | +16.61% | ABOVE |
| 150 SMA | $455.17 | +16.35% | ABOVE |
| 200 SMA | $444.57 | +19.12% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VRTX in an uptrend right now?
VRTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is VRTX overbought or oversold?
VRTX's RSI (14) is 81. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is VRTX outperforming the market?
VRTX has a Relative Strength (RS) Rating of 75 out of 99. VRTX is performing about average compared to the market.
Where is VRTX in its 52-week range?
VRTX is trading at $529.59, which is 100% of its 52-week high ($529.99) and 100% above its 52-week low ($362.50).
How volatile is VRTX?
VRTX has a Beta of 0.60 and 52-week volatility of 35%. It's less volatile than the S&P 500 - generally more stable.